Michael J Birrer, MD, PhD
Articles by Michael J Birrer, MD, PhD
Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.
Key Data Highlights in Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.
Treatment of Rare Tumors in Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.
Investigative Therapies in Recurrent Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.
Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.
Antibody-Drug Conjugates in Ovarian Cancer Treatment
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.
The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.
PARP Inhibitor Resistance in Ovarian Cancer Treatment
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.
Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.
The Rationale for PARP Inhibition plus IO in Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.
Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.
Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.
PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.
PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.
Recent Updates in PARP Inhibitor Indications for Ovarian Cancer
ByBradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS,Shannon N. Westin, MD, MPH, FACOG,Michael J Birrer, MD, PhD Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.
